Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Clinical trial NCT06501625 · RECRUITING
Trial details
- NCT number
- NCT06501625
- Sponsor
- Institut de Recherches Internationales Servier
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-16
- Primary completion
- 2026-07-23
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.